Altria Group: Focus on Oral Tobacco Products and Growth

Dec.01.2022
Altria Group: Focus on Oral Tobacco Products and Growth
Altria Group's focus on oral tobacco products leads to expected growth in adjusted earnings per share by 4.5-6%.

US tobacco company Altria Group, Inc. (MO) appears well-prepared to tackle rising costs and weak cigarette sales by focusing on oral tobacco products, thanks to its strong pricing power. The company is expecting adjusted earnings per share between $4.81 and $4.89 in 2022, a growth of 4.5-6% compared to $4.61 in 2021.


Let's delve deeper and take a closer look.


Factors supporting Altria


Due to the serious health risks associated with smoking, consumers are turning to products with reduced risk or no smoke. Altria has been adapting to the changing market by offering a variety of oral, electronic, and heated tobacco products. Altria, through its subsidiary Helix Innovations, owns on!, a popular tobacco-derived nicotine (TDN) pouch product. Management believes that on! is worth mentioning as part of Altria's smoke-free product portfolio as oral TDN products are becoming more popular in the US due to their low-risk claims. In the third quarter of 2022, the net revenue of the oral tobacco products segment increased by 7% compared to the same period last year to $665 million due to price increases. The domestic shipment volume of this segment increased by 1.3%, mainly due to changes in trade inventory, industry growth rate, and calendar differences, with reported shipping volume soaring by about 70%. Additionally, the retail market share of oral tobacco increased compared to the previous quarter, reaching 5.2 share points in the third quarter.


Altria Group surprises with price, consensus, and earnings per share.


Tobacco giant Altria has remained strong thanks to its powerful pricing ability, even during periods of weak cigarette shipments and increased taxes. While higher prices may lead to decreased cigarette consumption, it appears that due to the addictive nature of cigarettes, smokers are willing to accept price hikes. In Q3 of 2022, higher pricing supported revenue in Altria's smokeable and oral tobacco product segments. Additionally, higher pricing helped the adjusted operating company income for both segments. This trend may continue to have room for growth.


Barrier or obstacle.


Cost inflation and rising natural gas prices were unfavorable factors in the third quarter. Additionally, wage costs increased. The continued presence of these factors remains a concern. Management's outlook for 2022 takes into account planned investments related to costs aimed at improving the digital consumer engagement system, strengthening research, development, and regulatory readiness costs for smokeless products, and supporting marketing activities for the company's smokeless products. The outlook also includes expectations for inflation in settlement agreement costs, as well as direct and indirect material costs. In the third quarter of 2022, Altria's net income decreased by 3.5% year-on-year to $6.55 billion, due to lower revenue from the wine segment divestment in October 2021 and decreased revenue from the combustible products segment. Excluding excise taxes, revenue decreased by 2.2% to $5.412 billion.


In the field of smoking products, net income decreased by 1.6% year-on-year to $5.882 billion due to decreased shipments and increased promotional investments. Domestic cigarette shipments fell by 9.2% year-on-year, primarily driven by industry decline and losses in retail market share. However, changes in trade inventory partially offset this impact. After adjusting for changes in trade inventory and other factors, estimates indicate that domestic cigarette shipments for smoking products decreased by 8%.


Bottom line


Overall, cigarette sales have been impacted by increased consumer health awareness and regulatory barriers. However, according to a third quarter earnings call with management, research suggests that despite price increases in the tobacco category compared to other categories, tobacco consumers are more likely to continue purchasing their preferred brands. Pricing power and advantages with smokeless tobacco products may keep Altria on a growth trajectory. The stock price of this third-ranked (hold) Zacks company has risen 1.5% over the past three months, compared to the industry's 1% increase.


2FIRSTS will continue to cover this topic, with updates available on the "2FIRSTS APP". Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Product | Philip Morris Japan Launches Ginza-Exclusive IQOS ILUMA i PRIME, Limited to 1,814 Units at First Global Flagship
Philip Morris Japan (PMJ) launched the IQOS ILUMA i PRIME Ginza Limited Model Set in Tokyo on September 4, 2026, alongside the opening of IQOS Flagship Ginza, the brand’s first global flagship store. The Oasis Blue edition is limited to 1,814 individually numbered units, with the figure derived from the store’s address at Ginza 1-8-14. The set also includes two Yamanaka-nuri glasses and special packaging, priced at JPY 11,980 and sold exclusively at the Ginza flagship.
Sep.07
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
The Philippines’ Bureau of Internal Revenue is intensifying enforcement against illicit vape and tobacco products ahead of the Christmas shopping season, directing regional and enforcement offices to strengthen monitoring of production sites, warehouses, distribution channels and retail outlets. The BIR destroyed 240,550 illicit vape products in August with an estimated tax liability of about PHP1.53 billion. A nationwide tax-compliance operation in July also inspected 3,590 businesses involved in tobacco and vapor products.
Regulations
Sep.17 by 2Firsts Perspectives
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang Industrial Co., Ltd. has filed a patent application for an oral nicotine delivery product designed to let users actively adjust nicotine release. The product embeds two types of nicotine reservoirs with different wall thicknesses and positions inside a deformable matrix. Pressure applied with the tongue or lips can rupture the reservoirs and accelerate nicotine release. In simulated oral tests, several patent examples showed sharply higher peak nicotine release rates as applied force increased from 0 N to 1 N and 3 N. The filing explores a shift from preset release profiles toward user-triggered nicotine delivery.
Sep.01